drugset
drugset / Trial / NCT03158948

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock

NCT03158948 ↗

Phase 2 Completed 50 enrolled Inotrem
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of nangibotide versus placebo in adult patients with septic shock.

Timeline

Start
2017-07-03
Primary completion
2018-06-13
Completion
2018-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject nangibotide Peptide 0.3 mg/kg —
Subject nangibotide Peptide 1 mg/kg —
Subject nangibotide Peptide 3 mg/kg —

Indications

No indication recorded.